ENTAEnanta Pharmaceuticals, Inc.
Is the price fair?
At the top of its own P/E range. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Expensive vs its own history: P/E 45.9 vs a 27.4 median over 13 quarters (+68% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ENTA's price assumes
Enanta Pharmaceuticals, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 6.50× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 4.20
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 4.20
- EV / EBIToperating margin −90%: the multiple describes the denominator
- not meaningful
- Market capitalisation29.1 million shares, counted Aug 7, 2026
- $339M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.